Markets
← Back to Stocks
MRNA
MODERNA INC
Health Care · Biotechnology
$52.34
-0.15%
Vol: 0.1M
Araverus Market Read
Thursday, March 19, 2026
Patent settlement resolves LNP litigation overhang, powers vaccine developer forward
Moderna shares rose 10% in premarket trading on March 19, 2026 after the company settled its $950 million LNP patent dispute with Arbutus and Genevant, eliminating a major litigation overhang and providing clarity on core platform technology costs. However, the stock currently trades around $52 (down slightly from previous close), reflecting analyst caution due to concerns over revenue decline and execution risks in its pipeline despite strong 81% year-to-date gains. According to 12 analysts, the average rating is Hold with a 12-month price target of $33.0, representing 37.02% downside from current levels.
Price 50d 200d
Previous Market Reads
2 of 2 daysSector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $916.83 | -0.13% | -11.4% | 21.8x | 0.43 | $821.2B |
| JNJJOHNSON | $237.56 | +0.16% | -1.8% | 18.9x | 0.33 | $572.6B |
| ABBVABBVIE | $206.31 | -0.97% | -11.4% | 12.8x | 0.33 | $364.6B |
| MRKMERCK | $114.17 | -0.29% | -5.4% | 11.7x | 0.26 | $282.3B |
| UNHUNITEDHEALTH | $280.37 | -1.29% | -2.2% | 14.1x | 0.38 | $254.5B |
| AMGNAMGEN | $349.90 | -0.42% | -6.3% | 15.0x | 0.42 | $188.6B |
| ABTABBOTT | $107.19 | -1.12% | -4.5% | 17.2x | 0.74 | $186.3B |
| GILDGILEAD | $141.06 | -0.17% | -8.6% | 14.7x | 0.37 | $175.2B |
| TMOTHERMO | $470.21 | +1.18% | -6.2% | 17.5x | 0.97 | $174.7B |
Fundamentals
Market Cap$20.7B
P/E (TTM)—
Forward P/E-11.5
Beta1.35
Div Yield—
Prev Close$52.42
RSI (14-Day)
48Neutral
0305070100
52-Week Range
$22.28$52.34$59.55
From High-12.1%
From Low+134.9%
Moving Averages
50d SMA
$46.75+12.0%
200d SMA
$32.36+61.7%
Price above both MAs — bullish structure.
Returns
1W
-2.0%
1M
+12.3%
3M
+75.1%
6M
+109.4%
1Y
+54.8%
YTD
+69.6%
Volume
Today113K
20d Avg9.2M
Ratio0.01x